Shymaa Bilasy

Dr. Shymaa Bilasy

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 June 2024 in Viruses
Verified
Journal Article
Open access
PDF file
JDJackson Donald
Jackson Donald
SBShymaa Bilasy
Shymaa Bilasy
CYCatherine F. Yang
Catherine F. Yang
AEAhmed Elshamy
Ahmed Elshamy
Since the emergence of the SARS-CoV-2 virus in 2019, nearly 700 million COVID-19 cases and 7 million deaths have been reported globally. Despite most individuals recovering within four weeks, the Center for Disease Control (CDC) estimates that 7.5% to 41% develop post-acute infection syndrome (PAIS), known as ‘Long COVID’. This review provides current statistics on Long COVID’s prevalence, explores hypotheses concerning epidemiological factors, such as age, gender, comorbidities, initial COVID-19 severity, and vaccine interactions, and delves into potential mechanisms, including immune responses, viral persistence, and gut dysbiosis. Moreover, we conclude that women, advanced age, comorbidities, non-vaccination, and low socioeconomic status all appear to be risk factors. The reasons for these differences are still not fully understood and likely involve a complex relationship between social, genetic, hormonal, and other factors. Furthermore, individuals with Long COVID-19 seem more likely to endure economic hardship due to persistent symptoms. In summary, our findings further illustrate the multifaceted nature of Long COVID and underscore the importance of understanding the epidemiological factors and potential mechanisms needed to develop effective therapeutic strategies and interventions.

29 August 2025 in Viruses
Verified
Journal Article
Open access
PDF file
ADAakriti Dua
Aakriti Dua
BTBhavna Trehan
Bhavna Trehan
SBShymaa Bilasy
Shymaa Bilasy
CYCatherine F. Yang
Catherine F. Yang
AEAhmed Elshamy
Ahmed Elshamy
Background: Influenza, a primarily respiratory illness, frequently manifests with gastrointestinal (GI) symptoms including nausea, vomiting, diarrhea, and abdominal pain. In this review, we analyze mechanisms describing GI infiltration and subsequent involvement of the GI system during influenza infection. Direct mechanisms involve the presence of viral particles in the GI tract and binding to sialic acid receptor, α2,3 and α2,6 linkages. The influenza virus may gain access to gut tissue via swallowing of respiratory secretions, hematogenous spread, or lymphocytic migration via the lung–gut axis. Indirect mechanisms involve immune system dysregulation via cytokine, interferon, and leukotriene flux, upregulation of consequential apoptotic pathways, or gut microbiome dysbiosis. Together, they promote secondary GI opportunistic infections. These findings improve our knowledge of GI infiltration during influenza infection which may aid in effective clinical diagnosis and treatment, ultimately improving patient outcomes.

1 December 2017 in Egyptian Journal of Basic and Applied Sciences
Verified
Journal Article
Open access
SESoha S. Essawy
Soha S. Essawy
SBShymaa Bilasy
Shymaa Bilasy
HMHala Mohammad
Hala Mohammad
ASAly A.M. Shaalan
Aly A.M. Shaalan
The use of cisplatin for the treatment of cancer is accompanied by dose-dependent adverse effects. In colorectal cancer, there is upregulation of cyclooxygenase-2 (COX-2) expression increases prostaglandin E2 (PGE2) which in turn depresses apoptosis and potentiates invasion, angiogenesis, cell-proliferation and metastasis. This study investigates a possible synergistic function for celecoxib in cisplatin-based chemotherapy against chemically-induced colon carcinogenesis in mice. Mice received fifteen injections of 1,2-dimethylhydrazine dihydrochloride (DMH; 20 mg/kg/week, s.c.) to induce colon carcinogenesis and the normal control group received equal volumes of normal saline. Mice were randomly divided into five groups, (I) normal control group, (II) DMH control group (III) DMH + cisplatin (4 mg/kg/week, i.p.) group, (IV) DMH + celecoxib (10 mg/kg/day by gavage) group and (V) DMH + cisplatin + celecoxib group. Drugs were administered starting from week eleven until the end of the experiment (week 15). Colon specimens were used to evaluate histological grades, examine intratumoral expression of Bcl2, BAX and caspase-3 and the number of proliferating nuclei. The combination of cisplatin and celecoxib was effective against malignant transformation in mice with DMH-induced colonic aberrant crypt foci (ACF). The combination group showed improvement in histological grading, the highest caspase-3 expression and the lowest Bcl2/BAX ratio and reduction by approximately 50% of immunoreactivity for proliferating cell nuclear antigen (PCNA) compared to DMH control group. Addition of celecoxib to cisplatin regimen promotes apoptosis, suppresses tumor proliferation and augments the antitumor effect of cisplatin chemotherapy in the mouse model of DMH-induced ACF. Keywords: BAX, BCl2, Caspase-3, Celecoxib, Cisplatin, 1,2-Dimethylhydrazine, PCNA, Colonic AC

18 January 2024 in Viruses
Verified
Journal Article
Open access
PDF file
SBShymaa Bilasy
Shymaa Bilasy
TWTutik Sri Wahyuni
Tutik Sri Wahyuni
MIMohamed Mustafa Ibrahim
Mohamed Mustafa Ibrahim
AEAhmed Elshamy
Ahmed Elshamy
Since its discovery in 2019, SARS-CoV-2 still makes the headline news

13 May 2026 in Obesities
Verified
Journal Article
Open access
PDF file
JSJasjot Kaur Sandhu
Jasjot Kaur Sandhu
RKRia Kumar
Ria Kumar
SBShymaa Bilasy
Shymaa Bilasy
GCGratiana Chen
Gratiana Chen
CYCatherine F. Yang
Catherine F. Yang
AEAhmed Elshamy
Ahmed Elshamy
Binge-eating disorder (BED), defined as recurrent episodes of consuming large amounts of food in a short period of time while experiencing a loss of control, remains difficult to manage. Although several pharmacological options are available, they often provide limited long-term benefit and may cause adverse effects. Emerging evidence suggests that gut microbiota dysbiosis contributes to BED pathophysiology. Cytokine infiltration of the gut barrier ultimately causes neuroinflammation, highlighting the gut–brain axis as a potential therapeutic target. This systematic review and meta-analysis evaluated the effectiveness and safety of central nervous system-targeting pharmacotherapies and psychobiotics for BED. Cochrane Library, PubMed, and the Virtual Health Library were searched for randomized controlled trials published from January 2000 to January 2026. Eligible studies evaluated monotherapy with a central nervous system-acting drug or psychobiotics in clinically diagnosed BED populations. Twenty pharmacological trials (n = 2154) and five psychobiotic trials (n = 304) met the inclusion criteria. Risk of bias was assessed using the Cochrane RoB 2 tool, and pooled estimates were calculated using random-effects models. Pharmacological interventions showed a significant pooled effect versus placebo (Standard Mean Difference (SMD) = 0.307, 95% Confidence Interval (CI): 0.103–0.511, p = 0.003), although heterogeneity warrants cautious interpretation. Psychobiotics showed a moderate and significant effect (SMD = 0.680, 95% CI: 0.448–0.913; I2 (heterogeneity index) = 0%) and no reported adverse events. Overall, our study implies that psychobiotics may be a safe and potentially effective adjunctive approach for BED, but larger, well-designed trials are needed.